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Abstract 
Amyloid deposition, tangle formation, neuroinflammation and neuronal dysfunction 
are pathological processes involved in Alzheimer’s disease. However, the relative role 
of these processes in driving disease progression is still unclear. The aim of this PET 
study was to: 1) investigate longitudinal changes of microglial activation, amyloid and 
glucose metabolism, and 2) assess the temporospatial relationship between these three 
processes in Alzheimer’s disease. A group of eight patients with a diagnosis of 
Alzheimer’s disease (age = 66±4.8 years) and fourteen healthy controls (age = 65±5.5 
years) underwent T1 and T2 MRI, along with 11C-(R)-PK11195, 11C-PIB and 18F-
FDG PET scans for microglial activation, amyloid deposition and glucose metabolism. 
All patients were followed up with repeated MRI and three PET scans after 16 months. 
Parametric maps were interrogated using Region of Interest analysis, Statistical 
Parametric Mapping, and between-group correlation analysis at voxel level using 
Biological Parametric Mapping. At baseline, patients with Alzheimer’s disease 
showed significantly increased microglial activation compared to the control subjects. 
During follow-up, for the first time we found that, while there is a progressive 
reduction of glucose metabolism, there was a longitudinal increase of microglial 
activation in the majority of the Alzheimer’s disease patients. Voxel-wise correlation 
analysis revealed that microglial activation in patients with Alzheimer’s disease was 
positively correlated with amyloid deposition and inversely correlated with regional 
cerebral metabolic rate at voxel-level over time. Even though one of the limitations of 
this study is the lack of longitudinal follow-up of healthy control subjects, this study 
demonstrates that there is persistent neuroinflammation throughout the Alzheimer’s 
disease process with associated synaptic dysfunction and reduced glucose metabolism. 
Voxel-wise correlation analysis suggests that neuroinflammation is associated with 
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localised amyloid deposition and glucose metabolism over time, however, the level of 
inflammation could also occur independently of amyloid pathology, especially in the 
later stages of Alzheimer’s disease.  
Keywords: Alzheimer’s disease; microglia; amyloid imaging; neuropathology; 
dementia. 
 
Abbreviations: rCMRGlc = regional cerebral metabolic rate; TSPO = 18-kDa 
mitochondrial translocator protein; 18F-FDG =18F-2-fluoro-2-deoxyglucose; ROI = 
region of interest; SPM = statistical parametric mapping; BPM = biological 
parametric mapping; MNI = Montreal Neurologic Institute; CNS = central nervous 
system; NP3 = neuritic plaque; ROI = Region of interest. 
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Introduction  
Alzheimer’s disease is a progressive neurodegenerative disease characterised by 
extracellular β-amyloid plaques and intracellular neurofibrillary tau tangles. It has 
been demonstrated that amyloid plaques are surrounded by activated microglia, the 
resident macrophages of the central nervous system (CNS) (Edison, et al., 2013; 
Marlatt, et al., 2014; Sanchez-Guajardo, et al., 2013). However, the longitudinal 
relationship between amyloid deposition, neuroinflammation and neuronal 
dysfunction in Alzheimer’s disease is still unclear. The modified amyloid cascade/ 
neuroinflammation hypothesis suggests that amyloid deposition is the primary event, 
inducing microglial activation which releases neurotoxic substances causing neuronal 
damage and neurodegeneration. However, it is known that microglial activation can 
also be protective by promoting clearance of toxic amyloid oligomers in the early 
stages of Alzheimer’s disease pathogenesis (Schott and Revesz, 2013).  
As the disease progresses, the microglia aggregate around the amyloid deposits, both 
in the brains of patients with Alzheimer’s disease at post-mortem and in transgenic 
mice models of Alzheimer’s disease. Their inability to remove amyloid plaques in late 
disease has been implicated as a cause of accelerated neurodegeneration (Akiyama, et 
al., 2000; Schott and Revesz, 2013). It is now established that there are at least two 
phenotypes of microglia, M1 and M2, which are respectively pro-inflammatory and 
neuroprotective. These microglial phenotypes can interchange during the disease 
process. There is increasing evidence to suggest that neuroinflammation is an 
essential and common feature in most neurodegenerative diseases (Amor, et al., 2010; 
Perry, et al., 2010). It has also been reported that in vivo levels of microglial 
activation in Alzheimer’s disease cortex correlate with performance on cognitive 
testing and inversely with levels of glucose utilisation (rCMRGlc) (Edison, et al., 
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2008; Kreisl, et al., 2013a; Morimoto, et al., 2011). Regional cerebral metabolic rate 
(rCMRGlc) reflects local synaptic activity and so a reduction indicates neuronal 
dysfunction (Ewers, et al., 2013; Landau, et al., 2011).  
PET imaging with the tracers 11C-(R)PK11195, 11C-PIB and 18F-FDG allows us to 
investigate levels of microglial activation, fibrillar amyloid deposition and reductions 
of rCMRGlc in vivo in the human brain (Ewers, et al., 2013; Schuitemaker, et al., 
2013; Yokokura, et al., 2011). Activated microglial cells overexpress the 18-kDa 
mitochondrial translocator protein (TSPO) which binds the isoquinoline 11C-(R)-
PK11195. 11C-PIB binds to fibrillar -amyloid present in both neuritic and diffuse 
plaques in the cortex and striatum of Alzheimer’s disease patients, but not to 
amorphous -amyloid deposits. 18F-FDG (18F-2-fluoro-2-deoxyglucose) is a marker 
of hexokinase activity, the rate limiting enzyme controlling rCMRGlc, and reflects 
neural synaptic function (Nordberg, et al., 2010; Sokoloff, 1981). 
Previously, we have demonstrated increased levels of cortical and subcortical 
microglial activation in Alzheimer’s disease and Parkinson’s disease (Edison, et al., 
2013; Edison, et al., 2008). However, to date, no studies have evaluated the 
longitudinal in vivo relationship between cortical neuroinflammation/microglial 
activation, fibrillar amyloid load and rCMRGlc in Alzheimer’s disease simultaneously. 
Here we hypothesise that microglial activation detected with 11C-(R)-PK11195 PET 
persists throughout the disease and acts to drive the progressive neuronal damage in 
Alzheimer’s disease. In this study, for the first time, we evaluated the longitudinal 
relationship between microglial activation, amyloid and glucose metabolism in 
patients with Alzheimer’s disease using 11C-(R)-PK11195, 11C-PIB and 18F-FDG PET 
with a region of interest (ROI) analysis and statistical parametric mapping (SPM). We 
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have also evaluated between-group and single subject correlations of these parameters 
at a voxel level using biological parametric mapping at baseline and follow-up.  
Materials and methods 
Demography 
Subjects aged from 50 to 75 were recruited from the hospitals in and around London. 
We recruited eight Alzheimer’s disease patients who had MRI scans and 11C-(R)-
PK11195, 11C-PIB and 18F-FDG PET scans at baseline. We evaluated 14 healthy age-
matched controls for 11C-PIB PET, eight control subjects for 11C-(R)-PK11195 PET 
and eight control subjects for 18F-FDG PET with arterial input. We had approval to 
perform only two PET scans in healthy control subjects. The average delay between 
the two PET scans was 10 days and all Alzheimer’s disease patients underwent all 
three PET scans within 28 days at baseline and follow-up. Patients with Alzheimer’s 
disease were diagnosed based on the DSM-IV and NINDS-ADRDA criteria (Jack, et 
al., 2012; McKhann, et al., 1984). Eight patients with Alzheimer’s disease had repeat 
11C-PIB PET and 11C-(R)-PK11195 PET after a mean follow-up of 17 months and five 
patients with Alzheimer’s disease also had repeat 18F-FDG PET.  
MRI Scanning 
MRI scans were obtained using a 1.5 Tesla GE scanner. T1 volumetric MRI (3D T1 
volume, pulse sequence RF-Fast, acquisition times TR 30 ms, TE 3 ms, flip angle 30 
degrees, field of view (FOV) 25 cm, matrix 156 x 256, voxel dimensions 
0.98 x 0.98 x 1.6 mm) were acquired for co-registration and assessment of atrophy, 
while T2 weighted images were acquired to rule out any structural abnormality. 
11C-PIB PET 
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Subjects had an intravenous bolus injection of 11C-PIB (mean injected dose 370 
(SD±20) MBq), and were scanned using a Siemens ECAT EXACT HR+ scanner 
(Brix, et al., 1997). Dynamic emission scans were acquired in three-dimensional 
mode over 90 minutes. All data processing and image reconstruction were performed 
using standard Siemens software which included scatter correction.  
Statistical parametric mapping software (SPM8) was used to spatially transform 
individual PIB PET images into their corresponding MRI space by: 1) segmenting 
individual MRIs into grey matter, white matter and CSF, 2) thresholding voxels with 
a  >50% probability of containing grey matter to create individual grey matter 
binarised images, 3) transforming the Hammers probabilistic atlas in standard MNI 
space into the individual's MRI space, 4) co-registering individual 60-90 minute 11C-
PIB PET onto the corresponding MRI. The grey matter binarised image was then 
convolved with the atlas in Analyze 11 to create an individualised object map. Finally, 
the 60-90 minute 11C-PIB RATIO images were created by dividing the parametric 
11C-PIB uptake image by the ROI value of cerebellar grey matter uptake. The RATIO 
images were then sampled in the following regions: anterior and posterior cingulate, 
thalamus, hippocampus, frontal, temporal, parietal, occipital and composite cortical 
region.  
11C-(R)-PK11195 PET 
11C-(R)-PK11195 was manufactured by Hammersmith Imanet plc. 11C-(R)-PK11195 
PET was performed using an ECAT EXACT HR++ scanner, which has an axial field 
of view of 23.4 cm and 95 transaxial planes. A mean dose of 296 (SD ± 18) MBq 11C-
(R)-PK11195 was injected intravenously over 20 seconds. The 11C-(R)-PK11195 PET 
dynamic emission scans were acquired in list mode over 60 minutes and rebinned into 
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18 time frames post-acquisition. Parametric images of 11C-(R)-PK11195 binding 
potential (BP), reflecting Bmax/Kd, were generated with a simplified tissue reference 
two brain compartmental model (SRTM). As Alzheimer’s disease patients have a 
widespread distribution of pathological changes, no single region free of disease can 
be identified as a reference for non-specific tracer binding. Cluster analysis was, 
therefore, used to extract and identify a distributed cluster of voxels that mirrored a 
normal population cortical reference input function for each individual Alzheimer’s 
subject. We have introduced this computational methodology that enables the 
extraction of a reference cluster from 11C-(R)-PK11195 dynamic PET studies 
(Turkheimer, et al., 2007). The algorithm matches the time activity curve (TAC) of 
each pixel to the kinetics of six pre-defined tissues (normal grey and normal white 
matter, skull, muscle, grey matter with reactive microglia, vasculature that is rich in 
the receptor in endothelial cells and smooth muscles) obtained from a database of 
control subjects and patients. The reference TAC is calculated as the population 
average of normal grey matter. The clustering code is implemented in the software 
package SUPERPK (Imperial Innovations, Imperial College London) written in 
Matlab (The Mathworks Inc., Natick MA). The use of an appropriate reference not 
only increases the sensitivity of the quantification procedure to the specific signal 
from microglia but also minimises the sensitivity of the calculated binding potential 
(BP), obtained by the modelling procedure, to changes in blood flow. Our unit has 
validated the use of the SRTM with a reference input function defined by cluster 
analysis as the most reproducible and sensitive technique for generating BP maps 
(Anderson, et al., 2007). 11C-(R)-PK11195 PET BP images were transformed into the 
individual's corresponding MRI space, and the same sets of cortical regions as those 
used to sample 11C-PIB PET images were applied.  
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18F-FDG PET 
Subjects were asked to fast for 4 hours before the injection of 18F-FDG (186±8 MBq). 
The FDG dynamic emission scan was acquired over 60 minutes with continuous 
online whole blood sampling for the first 15 minutes while discrete whole blood and 
plasma samples were taken at 5, 10, 15, 20, 30, 40, 50 and 60 min. All subjects had 
radial artery cannulation and fasting plasma glucose levels were measured at the 
beginning and end of the scan. Parametric maps of absolute rCMRGlc were created 
by applying spectral analysis to brain time activity curves using an arterial plasma 
input function (Edison, et al., 2013). 
Voxel level correlations using biological parametric mapping 
To evaluate correlations between patterns of tracer uptake at a voxel level, Z-score 
maps were created initially for each individual subject using SPM8. The Z maps 
reflected individual clusters of significantly raised microglial activation and amyloid 
deposition and reduced glucose metabolism, relative to the normal mean and variance. 
Z-score maps for microglial activation, amyloid deposition and rCMRGlc were 
created using the formulae:  
𝑍[11𝐶](𝑅)𝑃𝐾11195 =  
[11C](𝑅)𝑃𝐾11195𝐵𝑃− Ẋ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[11𝐶](𝑅)𝑃𝐾11195𝐵𝑃
SD of 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[11𝐶](𝑅)𝑃𝐾11195𝐵𝑃
  
𝑍 [11𝐶]𝑃𝐼𝐵 =  
[11C]PIB− Ẋ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[11C]PIB
SD of 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[11C]PIB
 , 
𝑍 [18𝐹]𝑟𝐶𝑀𝑅𝐺𝑙𝑐 =  
[18F]rCMRGlc −  Ẋ 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[18F]rCMRGlc
SD of 𝐶𝑜𝑛𝑡𝑟𝑜𝑙[18F]rCMRGlc
 
where Z denotes Z score map, Ẋ denotes mean, and SD denotes standard deviation. 
The BPM toolbox runs on the Matlab (The Mathworks Inc) platform and is integrated 
into the SPM software package (Riedel, et al., 2009). The BPM toolbox performs 
multimodal correlations, ANCOVA and multiple regressions at a voxel-level using 
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the general linear model thereby providing sophisticated voxel-wise comparisons 
across imaging modalities. The BPM toolbox was applied to individual Z-score maps 
to perform correlations between cluster levels of microglial activation, amyloid load, 
and glucose metabolism in Alzheimer's disease. 
SPM interrogations of baseline and follow-up data 
Initially, all PET and MRI images of Alzheimer’s disease subjects and healthy 
controls were normalised into MNI (Montreal Neurologic Institute) standard space by 
spatially transforming the image using the SPM8 T1 MRI template and smoothed 
using a 6x6x6 mm filter.  
With 11C-(R)-PK11195 PET data, clusters of significantly increased uptake in patients 
with Alzheimer’s disease compared with healthy controls were interrogated at a voxel 
level with SPM8 using a cluster threshold of P<0.01 for significance with an extent 
threshold of 50 voxels. Follow-up scans were compared with those of control subjects 
using the same parameters.  
With 11C-PIB PET, clusters of significantly increased uptake in patients with 
Alzheimer’s disease compared with healthy controls were interrogated at a voxel level 
with SPM8 using an initial cluster threshold of P<0.000005 for significance and an 
extent threshold of 200 voxels. The same procedure and thresholds were performed 
for the follow-up 11C-PIB scans. The supervised cluster was calculated at baseline and 
follow-up separately. As microglial activation is a dynamic process, in this analysis 
we considered both increases and decreases of both tracers over time.  
With 18F-FDG, five out of eight subjects who completed both baseline and follow-up 
18F-FDG scans were included in the longitudinal analyses. To detect significant 
changes in rCMRGlc over time at a voxel-level, significant reduction of glucose 
metabolism in patients with Alzheimer’s disease compared to healthy controls was 
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interrogated at a cluster threshold of P<0.01 with extent threshold of 50 voxels at 
baseline and follow-up. 
Single subject volume of interest analysis and 3D Tmap 
To evaluate the individual changes in ROI findings for 11C-PIB, 11C-(R)-PK11195 
and 18F-FDG uptake after follow-up, we performed single subject volume of interest 
analyses. Since within subject changes in microglial activation occur throughout the 
cortex and are inhomogeneous, a pre-defined ROI approach is not ideal for detecting 
focal increases or decreases in small subregions or a subsequent spread across 
different regions. To deal with this, we created individualised object maps based on 
the locations of increased microglial activation, increased amyloid deposition, and 
decreased rCMRGlc in each subject identified using single subject SPM analysis, 
where each single subject was compared against a group of controls. For each subject, 
composite ROIs of increased microglial activation and amyloid deposition, and 
decreased rCMRGlc were created by extracting the regions of increased microglial 
activation and amyloid deposition, and reduced rCMRGlc following single subject 
SPM analysis in SPM8. The 11C-(R)-PK11195 BP, 11C-PIB RATIO and rCMRGlc 
parametric images were then sampled for each individual subject (Edison, et al., 
2013). Single subject analysis was performed for the control subjects for all the three 
tracers as well. 
We also generated single subject 3D intensity T-maps using MATLAB, in which 
significant clusters of microglial activation, amyloid deposition, and hypometabolism 
were displayed as surface plots, where the colour intensity reflects the T-score for the 
corresponding voxel. This allows a clear visualisation of the changes in microglial 
activation, amyloid, and glucose metabolism during follow-up.  
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Results 
Demographically, Alzheimer’s disease patients were aged from 51-74 with a mean of 
66.4±4.8 years, while the controls were aged from 54-75 with a mean of 65±5.5 years. 
5/8 Alzheimer’s patients and 9/16 healthy controls were female. We detected no 
significant between-group differences in age, age range or gender. The mean MMSE 
score deteriorated from 21/30 to 17/30 over a 17-month follow-up period in the 
patients with Alzheimer’s disease. Individually, apart from one Alzheimer’s patient 
who maintained the same MMSE score (25/30), and another subject whose MMSE 
score went up from 21 to 22, the other 6/8 Alzheimer’s patients showed further 
decline of around 5 points in their neuropsychological test during follow-up. Apart 
from one control who had some increase in amyloid deposition (based on mean 
+2SD), all healthy controls included in this study were negative for 11C-PIB uptake 
based on a 1.41 cut-off for 11C-PIB uptake RATIO (Supplementary Table 3). At 
baseline, 7/8 Alzheimer’s patients were 11C-PIB positive, all Alzheimer’s patients 
became 11C-PIB positive during the follow-up, using a cut of mean +2SD (Table 1). 
Three of the Alzheimer’s disease patients were on donepezil and one was on 
rivastigmine. One patient who was on donepezil maintained the same MMSE (25/30) 
during follow-up. In this study, none of the subjects had rheumatoid arthritis or other 
autoimmune diseases, as these subjects were excluded from the study. 
Around 2% of all Alzheimer’s patients who have early onset symptoms occurring 
before the age of 65 years are classified as early-onset Alzheimer’s disease (EOAD). 
It has been demonstrated that EOAD subjects have more rapid and severe cognitive 
deterioration than the population with late-onset Alzheimer’s disease (LOAD) (Kreisl, 
et al., 2013b). The current study recruited five EOAD patients (<65 years) who had 
more rapid elevation of microglial activation and more severe clinical deterioration 
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than three LOAD patients, with average drop of 5 points for EOAD and 1 point for 
LOAD in MMSE, while no significant difference was detected for CDR 
longitudinally between EOAD and LOAD. All EOAD patients demonstrated 
longitudinal increases in whole brain microglial activation compared to baseline, 
while amyloid deposition was increased in individual subjects, with associated 
reduction in glucose metabolism. (Table 1)  
11C- (R)-PK11195 PET 
At baseline, ROI analysis detected increased microglial activation in patients with 
Alzheimer’s disease compared to controls (mean increase of 30%, P<0.03) in frontal, 
temporal, parietal, occipital cortical regions, hippocampus and striatum (Fig. 1 and 
Table 2A). Using single subject VOI analysis, we found that all Alzheimer’s disease 
subjects had increased microglial activation as detailed in Table 3. Using SPM 
analysis, we detected significantly increased microglial activation in similar regions 
(cluster threshold P<0.01; extent threshold 50 voxels) (Fig. 2A, Supplementary Table 
1).  
After 16 (±3.6) months follow-up, the mean global 11C-(R)-PK11195 BP as a measure 
of microglial activation increased from 30% (P<0.03) to 46% (P<0.01) at 17 months 
follow-up (Table 2A and Fig. 2B). Using single subject analysis, we found that the 
total microglial activation (volume of interest (VOI) of activated microglia in a single 
subject using SPM analysis) was increased longitudinally in six out of eight patients 
with Alzheimer’s disease, while the other two subjects showed a reduction in 
microglial activation (Table 3). Clinically 6/8 Alzheimer’s patients showed 
progressive cognitive deterioration as evidenced by reduction in MMSE, while one 
patient who maintained the same MMSE score (25/30) showed relatively stable 
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amyloid load and minimum increase in microglial activation during follow-up, while 
another subject had MMSE scores changed from 21/30 to 22/30 and showed an 
increase in microglial activation with a relatively stable amyloid (Table 1). Control 
subjects did not show any significant increase in the single subject VOI analysis. 
 11C-PIB PET 
At baseline, ROI analysis demonstrated a significant increase in the amyloid load (66% 
increase, P<0.000007) in all cortical regions of Alzheimer’s disease cases (Table 2B). 
The voxel-wise SPM analysis of 11C-PIB uptake in Alzheimer’s disease relative to 
control subjects revealed significantly increased amyloid load (cluster threshold 
P<0.000005 and extent threshold of 200 voxels) (Fig. 2C and 2D).  
Longitudinally, no significant group changes were seen in 11C-PIB uptake for patients 
with Alzheimer’s disease. Individually, six patients with Alzheimer’s disease 
demonstrated longitudinal increased microglial activation; three subjects individually 
showed a significant increase in extent of amyloid deposition (25-237%) while the 
other three showed minor increases (1-6%) at follow-up. Interestingly, the two 
patients with Alzheimer’s disease who showed a reduction in amyloid deposition 
longitudinally also showed a reduction in microglial activation. Control subjects did 
not show any significant increase in the single subject VOI analysis. 
18F-FDG PET 
Compared to controls, Alzheimer’s disease cases showed an 11% significant 
reduction of composite cortical rCMRGlc (P<0.02) compared to controls on ROI 
analysis which further reduced to 17% (P<0.002) at follow-up (Table 2C). SPM 
analysis at follow-up also showed an increased extent of glucose hypometabolism in 
temporal lobe, hippocampus, amygdala, parietal lobe and occipital lobe (Fig. 2F) 
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compared with baseline (Fig. 2E) (voxel threshold of P<0.01; extent threshold 50 
voxels). 
A further significant reduction in rCMRGlc was also confirmed at follow-up for the 
Alzheimer’s disease group compared with baseline, applying Student's paired t-test, to 
the composite cortical region (−18%, P<0.001), anterior cingulate, posterior cingulate, 
thalamus, frontal lobe, temporal lobe, parietal lobe and occipital lobe, including 
subcortical regions in medial temporal lobe, hippocampus and amygdala (Fig. 2E and 
2F). Individually, all patients with Alzheimer’s disease showed further reductions in 
mean rCMRGlc at follow-up and an increased extent of hypometabolism (51% to 
359%). Control subjects did not show any significant increase in the single subject 
VOI analysis. 
Voxel level correlations 
A positive correlation was found at baseline between distributions of increased 11C-
PIB and 11C-(R)-PK11195 uptake in Alzheimer’s disease using the BPM toolbox with 
a voxel threshold of P<0.05 and extent threshold of 50 voxels (Fig. 3A). There was a 
less pronounced positive correlation at follow-up (Fig. 3B). A negative correlation 
was found at baseline between amyloid load and glucose metabolism using a cluster 
threshold of P<0.05 and extent threshold of 50 voxels (Fig. 3C). This correlation was 
more extensive at follow-up (Fig. 3D). A negative correlation was also observed 
between microglial activation and cerebral glucose metabolic rate at baseline using a 
voxel threshold of P<0.05 and extent of 50 voxels (Fig. 3E). (Supplementary Table 1)  
3D visualisation 
We used 3D intensity T maps to visualise individual changes of neuroinflammation, 
amyloid deposition and glucose metabolism, as shown in fFg. 4, where significant 
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clusters of increased microglial activation, amyloid deposition, and hypometabolism 
in a single subject against healthy controls were displayed with colour intensity to 
reflect the voxel level T-score at baseline and follow up. During follow-up, in one 
Alzheimer’s disease subject, the 3D intensity T-map revealed more clusters with 
significantly increased microglial activation and progressive hypometabolism, and 
minimal increase in the amount of amyloid deposition in different regions (Fig. 4). 
Discussion  
This is the first pilot study evaluating, at a voxel-level, the longitudinal correlation 
between distributions of microglial activation, amyloid deposition and reductions of 
glucose metabolism in patients with Alzheimer’s disease using the three PET tracers: 
11C-(R)-PK11195, 11C-PIB and 18F-FDG. Here we have demonstrated that, as a group, 
microglial activation is increased in Alzheimer’s disease subjects at baseline and 
during follow-up compared to control subjects, and individually microglial activation 
increased from baseline to follow-up in 75% of Alzheimer’s subjects. 
It has been suggested that microglial activation may be an early phenomenon in the 
Alzheimer’s disease process (Rubio-Perez and Morillas-Ruiz, 2012; Zimmer, et al., 
2014). However, in vivo longitudinal data in patients with Alzheimer’s disease are 
very sparse. Our PET findings demonstrate that there is persistent microglial 
activation in patients with Alzheimer’s disease whose distribution correlates at a voxel 
level with both amyloid load and reduced glucose metabolism. This is in line with the 
hypothesis that amyloid deposition triggers neuroinflammation, which then leads to 
neuronal dysfunction evidenced as a reduction of cerebral glucose metabolic rate. 
Individually, six of our eight patients with Alzheimer’s disease demonstrated 
increasing neuroinflammation over time. Similar findings have been reported by 
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pathological studies in which persistent glial activation was seen in Alzheimer’s 
disease associated with misfolded proteins (amyloid) and degenerative neurons (Perry, 
et al., 2010).  
Previous studies on levels of microglial activation in early mild cognitive impairment 
subjects compared with late Alzheimer’s subjects have shown conflicting reports. 
Yasuno et al. found a similar or higher level of microglial activation in patients with 
mild cognitive impairment than patients with Alzheimer’s disease when using 11C-
DAA1106 PET and suggested that microglial activation is predominant in the early 
stages of dementia reaching a plateau as disease progresses (Yasuno, et al., 2012). 
However, using 11C-(R)-PK11195 PET, Schuitemaker et al. found only a small cluster 
of increased microglial activation in Alzheimer’s dementia patients and no increases 
were detected in subjects with mild cognitive impairment (Schuitemaker, et al., 2013). 
This may have reflected a difference in analysis techniques as cluster analysis was not 
used to define the non-specific reference. Our PET study has demonstrated that there 
is persistent inflammation in the majority of the patients with Alzheimer’s disease 
during the course of their disease. This is in agreement with post-mortem studies 
which have shown significantly increased TSPO expression in all brain regions 
(Kravitz, et al., 2013).  
With 11C-(R)-PK11195 PET, six of our eight patients with Alzheimer’s disease 
demonstrated increasing microglial activation and stable amyloid levels over 17 
months while the other two subjects showed a reduction in glial activation, associated 
with a reduction in amyloid load. These findings may suggest that, while activated 
microglia can exert their effect for some years, eventually they may burn out. This 
phenomenon has been observed in a post-mortem study using microglial 
immunostaining for different Alzheimer’s disease stages according to the status of 
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phosphorylated tau in neuritic plaques (NP1-NP5). Xiang et al. found microglial 
immunostaining only increased in mid-to-late stages with moderate neuritic plaque 
(NP3), and the microglial staining was reduced in the more advanced phase with 
severe neuritic plaque (NP5) (Xiang, et al., 2006). The reduction in microglial 
staining was more pronounced if the toxic insult (amyloid) was also decreasing.  
Our two patients with Alzheimer’s disease with reduced microglial activation on 
follow-up both had lower baseline MMSE scores and showed a progressive 
deterioration in cognitive function, despite the fact that their amyloid load was also 
decreasing. However, the progressive reduction seen in their glucose metabolism 
suggests that on-going neuronal damage was occurring despite reduction in amyloid 
levels. One could argue that, once the neuronal damage sets in, it is progressively 
causing reduction in glucose metabolism.  
18F-FDG PET studies have demonstrated a significant longitudinal reduction in 
rCMRGlc in patients with Alzheimer’s disease compared to baseline across cortical 
regions (Kadir, et al., 2012). The longitudinal decline in rCMRGlc was consistently 
associated with cognitive decline in patients with Alzheimer’s disease and, in our 
study, individually all patients with Alzheimer’s disease revealed whole brain 
reduction in rCMRGlc, suggesting that, once synaptic dysfunction occurs, the disease 
is progressive (Ewers, et al., 2013; Gray, et al., 2012; Ossenkoppele, et al., 2014).  
Among eight who were clinically classified as Alzheimer’s disease patients, one 
patient with MMSE of 24/30 had negative amyloid at baseline with significant 
microglial activation in frontal, parietal and occipital lobe. After 17 months, this 
patient had a further decline in MMSE of 21/30. Based on the recent literature, it has 
been suggested that there is a group of amyloid negative AD patients, who clinically 
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deteriorate, and are classified as suspected non-Alzheimer’s pathophysiology (SNAP) 
(Chetelat, 2013). This subject demonstrated elevated microglial activation and 
reduced glucose metabolism both at baseline and during follow up. This subject 
demonstrated a small increase in amyloid load in anterior and posterior cingulate 
during follow-up, even though the levels were below the cut-off control mean+2SD. 
As regional involvement may vary in Alzheimer’s subjects, we have demonstrated 
that the best way to evaluate the relationship between amyloid, inflammation and 
synaptic dysfunction at a voxel level is to use BPM correlation. Here we have shown 
that increased amyloid deposition is associated with increased microglial activation 
which is in agreement with the modified neuroinflammation/amyloid cascade 
hypothesis (Barger and Harmon, 1997; Dickson, et al., 1993; Hardy and Higgins, 
1992; McGeer and McGeer, 2013). In our study, demonstration of positively-
correlated clusters of microglial activation and amyloid in temporoparietal region 
(including medial temporal lobe, parahippocampus and fusiform gyrus) in 
Alzheimer’s disease at baseline, and expansion of those regions in frontal and 
temporoparietal lobe during follow-up, provides further evidence that microglial 
activation detected by 11C-(R)-PK11195 is associated with progressive neuronal 
damage, even though the level of microglial activation varies at a voxel level within 
regions.  
In contrast to our positive correlation found in Alzheimer’s subjects, one study 
suggested an early stage inverse correlation between microglial activation and 
amyloid accumulation in posterior cingulate cortex (Yokokura, et al., 2011). Since 
Alzheimer’s disease is a heterogeneous disease, it is possible that, in the initial phase 
of the disease, microglia may be actively  involved in clearing of the amyloid, while 
as the disease progresses microglia could cause further neuronal damage (Griffin, et 
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al., 1995; Hjorth, et al., 2013; Mosser and Edwards, 2008; Woodling, et al., 2014) by 
releasing pro-inflammatory cytokines (Kumar Kaushik and Basu, 2013; Prokop, et al., 
2013; Varnum and Ikezu, 2012). It is possible that these subjects are in the early 
stages of the disease. 
In this study, we have demonstrated that there is a correlation between 
neuroinflammation and amyloid in most cortical regions, however, the precise 
locations of the regions with correlation showed a dynamic change over 17 months, 
suggesting that microglial activation detected by 11C-(R)-PK11195 is not static as the 
disease advances, supporting the theory of constant change in microglial activation. It 
may very well be due to the fact that once neuronal damage occurs, microglia retract 
their ramifications (go to the resting stage), while in other regions persistent activation 
remains. It is also possible that microglial reparative and destructive processes may be 
going hand in hand, even though in the later stages of the disease, the destructive 
process may the predominant feature (Perry, et al., 2010; Prokop, et al., 2013). In 
agreement with recent findings (Laforce, et al., 2014; Lowe, et al., 2014), an inverse 
correlation was found between 11C-PIB and 18F-FDG at baseline in subjects with 
Alzheimer’s disease with progressive involvement during follow-up, suggesting 
amyloid accumulation may induce progressive deficits in synaptic function as the 
disease advances.  
SPM localised large cortical areas with significantly increased microglial activation, 
amyloid plaques and hypometabolism in patients with Alzheimer’s disease, however, 
BPM correlations at voxel-level were restricted to smaller regions, suggesting that the 
voxels demonstrating correlated neuroinflammation, amyloid deposition and 
rCMRGlc were fewer. This could simply reflect the variance in these measurements, 
but BPM correlation also suggests that amyloid deposition was initially associated 
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with greater neuroinflammation and hypometabolism (McGeer and McGeer, 2002), 
but as the disease progresses, microglial activation and hypometabolism increase 
independent of amyloid due to other on-going pathological processes and chronic pro-
inflammatory environment (Blasko, et al., 2004; Block, et al., 2007; Eikelenboom, et 
al., 2012). Consistent with our findings, a recent Alzheimer’s disease study 
demonstrated that brain regions with hypometabolism but low amyloid deposition 
may be related to on-going pathologies in functionally connected regions rather than 
locoregional amyloid toxicity (Klupp, et al., 2014). (Fig. 5) 
One of the limitations of this study is the small sample size of the subjects in the study. 
However, this pilot study provides insight into the longitudinal relationship between 
the three pathologies in Alzheimer’s disease. In a future study, a larger sample size 
with evaluation of subjects with mild cognitive impairment progressing to 
Alzheimer’s disease will be used to fully ascertain the longitudinal relationship 
between microglial activation, amyloid and rCMRGlc. This study would have 
benefitted from the longitudinal follow-up of the control subjects with three PET 
scans, and the absence of longitudinal follow-up in controls could limit our 
interpretation, even though we do not anticipate the same level of increase in 
microglial activation in healthy control subjects. 11C-(R)-PK11195 PET has low 
signal-to-noise ratio, and we are now evaluating second generation TSPO tracers with 
a higher specific binding than 11C-(R)-PK11195.  
In conclusion, we have demonstrated for the first time that, while the amyloid load in 
patients with Alzheimer’s disease is relatively stable over time, there is an increase in 
microglial activation in the majority of the patients and a significant progressive 
reduction in rCMRGlc. In cases where microglial activation levels fell over time, the 
amyloid load also reduced, but this did not prevent hypometabolism worsening. BPM 
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correlation demonstrated a positive correlation between amyloid and microglial 
activation and a negative correlation between microglial activation and glucose 
metabolism and amyloid and glucose metabolism, suggesting both amyloid and 
microglial activation could contribute to neuronal damage. 
 
Figure legends 
Fig. 1: Longitudinal ROI changes of 11C-(R)-PK11195, 11C-PIB uptake and 
rCMRGlc in each Alzheimer’s disease patient. (A) Longitudinal changes in 
microglial activation. (B) Longitudinal changes in amyloid. (C) Longitudinal changes 
in rCMRGlc. P-Cingulate = Posterior Cingulate; BP = Binding Potential; rCMRGlc = 
regional cerebral metabolic rate. 
Fig. 2: The clusters of significantly increased 11C-(R)-PK11195 BP and 11C-PIB 
and reduced rCMRGlc in patients with Alzheimer’s disease compared to 
controls at baseline and follow-up. (A) and (B) demonstrate the clusters of 
significantly increased 11C-(R)-PK11195 in the cortical regions among eight 
Alzheimer’s disease patients compared to eight healthy control subjects at baseline 
and follow-up, respectively, with the same voxel threshold of P<0.01 and extent 
threshold of 50 voxels. (C) and (D) show clusters of significantly increased 11C-PIB 
binding in the cortical regions in eight patients with Alzheimer’s disease compared to 
fourteen healthy control subjects at baseline (P<0.000005 and extent of 200 voxels) 
and follow-up (P<0.000001 and extent of 200 voxels). (E) and (F) reveal clusters of 
significantly reduced rCMRGlc uptake in the temporoparietal cortex in eight patients 
compared to healthy controls using a voxel threshold of P<0.01 and extent threshold 
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of 50 voxels at baseline and follow-up, respectively. Supplementary Table 1 details 
the corresponding significant clusters. rCMRGlc = regional cerebral metabolic rate. 
Fig. 3: Positive correlation between microglial activation and amyloid load, as 
well as the negative correlation between amyloid load and glucose metabolism in 
Alzheimer’s subjects at baseline and during follow-up. The upper panel shows 3D 
intensity T-map of BPM correlation in sagittal view, while the lower panel shows the 
same correlation using SPM single subject render image. With BPM analysis, (A) and 
(B) show positive correlations between 11C-PIB RATIOs and 11C-(R)-PK11195 BP in 
temporal, frontal, and parietal lobe of patients with Alzheimer’s disease using a 
threshold of P<0.05 with a 50-voxel extent at baseline and follow-up, respectively. (C) 
and (D) show negative correlation at baseline and follow-up between 11C-PIB and 
rCMRGlc using a threshold of P<0.05 with a 50 voxel extent. (E) shows negative 
correlation between 11C-(R)-PK11195 and rCMRGlc using a threshold of P<0.05 
with a 50 voxel extent at baseline. Supplementary Table 2 details the significant 
clusters. S 
Fig. 4: 3D intensity T-map of 11C-(R)-PK11195, 11C-PIB ratio and rCMRGlc for 
one Alzheimer’s disease subject (AD 2) at baseline and follow-up. The surface plot 
represents significant increase in the amyloid deposition, microglial activation, and 
reduction in glucose metabolism against the control group at baseline superimposed 
on a 3D matrix with sagittal view (left) and transverse view (right). During follow-up, 
in one AD subject, the 3D intensity T-map revealed more clusters with significantly 
increased microglial activation and progressive hypometabolism, and minimal 
increase in amount of amyloid deposition in different regions (Fig. 4). rCMRGlc = 
regional cerebral metabolic rate. 
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Fig. 5: Relationship between microglial activation and neurofibrillary tangle 
formation in Alzheimer’s disease. IL = interleukin; TNF = tumour necrosis factor; 
IFN = interferon; iNOS = inducible nitric oxide synthase. 
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Table 1 
Table 1: Longitudinal individual changes in regional mean for 11C-
(R)-PK11195 and 11C-PIB with clinical MMSE scores 
AD 
PK  
Frontal Temporal Parietal Occipital WB MMSE(b) MMSE(f) 
1 EOAD -43% -36% -50% -29% -41% 19 10 
2 EOAD 64% 45% 94% 53% 138% 21 22 
3 EOAD 14% 38% 30% 43% 27% 19 13 
4 LOAD -34% -10% -45% -24% -27% 24 21 
5 EOAD 24% 12% 48% 21% 24% 19 10 
6 LOAD -3% 3% 0% -2% -1% 25 25 
7 EOAD 21% 38% 33% 82% 30% 17 13 
8 LOAD 4% 7% 4% 4% 5% 24 23 
         
         
AD 
PIB  
Frontal Temporal Parietal Occipital WB MMSE(b) MMSE(f) 
1 EOAD -11% -15% -14% -12% -13% 19 10 
2 EOAD -3% 6% 5% 6% 2% 21 22 
3 EOAD 27% 23% 34% 24% 27% 19 13 
4 LOAD 5% 9% 5% 10% 7% 24 21 
5 EOAD 5% 2% 4% 3% 4% 19 10 
6 LOAD 1% 3% 3% 1% 2% 25 25 
7 EOAD 32% 22% 36% 23% 30% 17 13 
8 LOAD -3% -2% -5% -5% -3% 24 23 
LOAD = Late-onset Alzheimer’s disease; EOAD = Early-onset Alzheimer’s disease; Frontal 
= Frontal Lobe; Temporal = Temporal Lobe; Parietal = Parietal Lobe; Occipital = Occipital 
Lobe; WB = Whole Brain; MMSE(b) = MMSE baseline; MMSE(f) = MMSE follow-up. 
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Table 2: ROI analysis of cortical changes for 11C-(R)-PK11195, 11C-PIB and 18F-FDG in 
AD compared to controls, at baseline and during follow-up. 
11C-PK11195 A-Cing P-Cing Thalamus Striatum Hippo Frontal Temporal Parietal Occipital 
Baseline 
Mean 0.41 0.4 0.51 0.38 0.47 0.44 0.44 0.4 0.45 
SD 0.11 0.14 0.15 0.12 0.12 0.11 0.07 0.13 0.08 
% Increase1 22% 2% 32% 48% 37% 46% 33% 37% 26% 
P-value  0.0832 0.4383 0.0551 0.0100* 0.0150* 0.0112* 0.0052* 0.0481* 0.0193* 
 
Mean 0.46 0.49 0.48 0.43 0.48 0.45 0.48 0.44 0.52 
Follow-up SD 0.2 0.21 0.15 0.11 0.16 0.15 0.13 0.19 0.15 
 
% Increase1 37% 25% 25% 64% 39% 50% 48% 49% 45% 
 
P-value 0.0694 0.1297 0.1036 0.0011* 0.0275* 0.0179* 0.0061* 0.0470* 0.0086* 
 
Longitudinal 
% Increase2 
12% 23% -6% 13% 2% 2% 9% 10% 16% 
11C-PIB A-Cing P-Cing Thalamus Striatum Hippo Frontal Temporal Parietal Occipital 
Baseline 
Mean 2.13 2.11 1.34 1.89 1.34 2.01 1.8 2.02 1.73 
SD 0.63 0.58 0.27 0.61 0.26 0.55 0.49 0.53 0.37 
% Increase1 72% 72% 32% 57% 13% 74% 56% 74% 43% 
P-value  <0.0001* <0.0001* 0.0002* 0.0002* 0.02* <0.0001* <0.0001* <0.0001* <0.0001* 
 
Mean 2.18 2.22 1.38 2.03 1.42 2.1 1.87 2.14 1.8 
Follow-up SD 0.5 0.45 0.23 0.46 0.24 0.45 0.39 0.42 0.27 
 
% Increase1 3% 5% 3% 8% 6% 4% 4% 6% 4% 
 
P-value  <0.0001* <0.0001* <0.0001* <0.0001* 0.002* <0.0001* <0.0001* <0.0001* <0.0001* 
 
Longitudinal 
% Increase2 
2% 5% 3% 7% 6% 4% 4% 6% 4% 
18F-FDG A-Cing P-Cing Thalamus Striatum Hippo Frontal Temporal Parietal Occipital 
Baseline 
Mean 0.31 0.34 0.25 0.33 0.23 0.32 0.25 0.29 0.28 
SD 0.05 0.06 0.05 0.07 0.04 0.05 0.06 0.05 0.06 
% Increase1 4% -8% -15% -7% -8% -5% -15% -15% -15% 
P-value 0.3063 0.1367 0.0455* 0.1999 0.1191 0.2188 0.0412* 0.0194* 0.0253* 
 
Mean 0.26 0.26 0.22 0.33 0.19 0.29 0.23 0.25 0.27 
Follow-up SD 0.03 0.05 0.02 0.07 0.02 0.05 0.04 0.05 0.06 
 
% Increase1 -12% -30% -25% -8% -23% -14% -20% -27% -19% 
 
P-value 0.0317* 0.0022* 0.0035* 0.225 0.0003* 0.062 0.0094* 0.0080* 0.0304* 
  
Longitudinal 
% Increase2 
-16% -24% -12% 0% -17% -9% -8% -14% -4% 
36 
 
*p<0.05; <0.0001* = p<0.0001*; % Increase1 indicates the group-wise ROI comparison with 
healthy controls; % Increase2 indicates the group-wise ROI comparison with baseline. A-Cing 
= Anterior Cingulate; P-Cing = Posterior Cingulate; Hippo = Hippocampus; Frontal = Frontal 
Lobe; Temporal = Temporal Lobe; Parietal = Parietal Lobe; Occipital = Occipital Lobe.  
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Table 3: Changes in the volume of microglial activation and the volume of amyloid deposition in AD between baseline and follow-up 
AD PK volume PIB volume FDG volume 
Subject Baseline Follow-up 
Change in volume  
(% change) 
Baseline Follow-up 
Change in 
volume  
(% change) 
Baseline Follow-up 
Change in 
volume  
(% change) 
AD1 204649 26742 -177907 (-87%) 338747 157210 -181537 (-54%) 123631 375759 252128 (204%) 
AD2 16943 53223 36280 (214%) 374892 376803 1911 (1%) 243092 438798 195706 (81%) 
AD3 99337 373971 274634 (276%) 217421 225236 7815 (4%) 27355 125442 98087 (359%) 
AD4 162536 311870 149334 (92%) 27454 92410 64956 (237%) 263306 542304 278998 (106%) 
AD5 341955 83399 -258556 (-76%) 36697 15648 -21049 (-57%) 29410 44454 15044 (51%) 
AD6 41803 46645 4842 (12%) 273064 341343 68279 (25%) 
   
AD7 312547 829597 517050 (165%) 347069 366402 19333 (6%) 
   
AD8 36998 110810 73812 (200%) 560597 1094708 534111 (95%) 
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